Abbott Laboratories (NYSE: $ABT) announced Q1 fiscal 2025 results on Wednesday, April 16th. The healthcare firm posted $1.33 billion in net income. Adjusted earnings reached $1.09 per share, beating estimates of $1.07.
Revenue came in at $10.36 billion. This matched analyst projections but fell short of the $10.42 billion consensus from Zacks Research. The company recorded a 4% year-on-year revenue growth and 6.9% growth in organic revenue.
Abbott Laboratories expects earnings of $1.23–$1.27 per share in Q2. For fiscal 2025, it forecasts $5.05–$5.25 per share. The midpoint of this range is $5.15, aligning with analyst expectations.
The company’s operating margin rose to 16.3% from 13.9% last year. This points to improved cost management. EPS also climbed from $0.98 to $1.09 in Q1. Over five years, EPS has grown at 7.9% annually.
ABT’s long-term growth has been modest. The company’s five-year revenue growth rate stands at 5.7%. Revenue growth has slowed to 1% over the last two years. Organic revenue averaged 3.7% growth during this time.
ABT has repurchased 1.9% of its stock in the past five years. This contributed to EPS growth. It currently has a market cap of $218.9 billion.
Technical Analysis
ABT is now trading at $132.94, up 4.06% intraday. Volume has reached 6.02 million shares. The price opened at $129.70 and hit a high of $134.16.
The stock broke past the 50-day ($130.87) and 100-day ($123.97) moving averages. This shows growing bullish momentum. ABT also held support at $120 and rebounded strongly.
This technically signals a potential bullish pattern. If the current breakout holds, ABT may test $141.23, which marks a previous resistance zone.
The 200-day moving average at $117.93 remains well below the price. This supports the longer-term uptrend. A strong rally above $135 could confirm a new swing high. Higher than the previous immediate high and targeting $133.
The rising volume also signals strong demand. If the stock stays above $130, the next target is $141 previous high. A dip and retest to $120 support could offer short-term support.
Is It the Right Time to Buy?
ABT has returned 23.48% over the last 12 months. It outperformed the S&P 500’s 5.89% gain in the same period. YTD, ABT rose 18.03%, beating the index’s 9.06%.
Despite trailing the S&P 500 over five years, the stock shows renewed momentum. Revenue grew by 4% this quarter, and operating margins improved.
ABT pays a dividend of $2.36 per share with a yield of 1.87%. It went ex-dividend on April 15. Analysts expect EPS to grow 11.3% in the next 12 months.
Wall Street’s 12-month price target is $136.68. That’s near the current price. However, the bullish technical breakout may fuel more upside.
Analysts see 6.8% revenue growth over the next year. This suggests that demand for new products may rise. ABT’s Q1 results were steady, with no surprises.
If the uptrend continues and price holds above key levels, ABT may offer short-term opportunities. Investors should watch for sustained buying above $135.
Click Here For Updates on ABT – It’s FREE to Sign Up for Text Message Notifications!
Disclaimer: This website provides information about cryptocurrency and stock market investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for educational and informational purposes only. The owner of this website is not a registered investment advisor and does not offer investment advice. You, the reader / viewer, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment.
